Objective There is now overwhelming evidence that glycosylation changes during the development and progression of various malignancies. Altered glycosylation has been implicated in cancer, immune deficiencies, neurodegenerative diseases, hereditary disorders and cardiovascular diseases. Currently, antibodies are playing a central role in enabling the detection of glycoprotein biomarkers using a variety of immunodiagnostic tests. Nonetheless, antibodies do have their own set of drawbacks that limit the commercialization of antibody sensing technology. They suffer from poor stability, need special handling and require a complicated, costly production procedure. More importantly, they lack specificity because they bind only to a small site on the biomarker and are not able to discriminate, for instance, among different glycosylated proteins. The current antibody diagnostic technology has well recognized limitations regarding their accuracy and timeliness of diagnose of disease. This project will focus on research into the means of developing a generic, robust, reliable and cost-effective alternative to monoclonal antibody technology. The project aims to exploit concepts and tools from nanochemistry, supramolecular chemistry and molecular imprinting to provide highly innovative synthetic recognition platforms with high sensitivity and specificity for glycoproteins. Such novel type of platforms will make a profound and significant impact in the broad fields of biosensors and protein separation devices with applications in many areas such as biomedical diagnostics, pharmaceutical industry, defense and environmental monitoring. The proposed technology may open an untraveled path in the successful diagnosis, prognosis and monitoring of therapeutic treatment for major diseases such as cancer, immune deficiencies, neurodegenerative diseases, hereditary disorders and cardiovascular diseases. Fields of science engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensorsbiosensorsnatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesclinical medicinecardiologycardiovascular diseasesmedical and health sciencesclinical medicineoncologyengineering and technologymedical engineeringmedical laboratory technologydiagnostic technologies Programme(s) FP7-IDEAS-ERC - Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Topic(s) ERC-CG-2013-PE8 - ERC Consolidator Grant - Products and Processes Engineering Call for proposal ERC-2013-CoG See other projects for this call Funding Scheme ERC-CG - ERC Consolidator Grants Host institution THE UNIVERSITY OF BIRMINGHAM EU contribution € 1 894 046,00 Address Edgbaston B15 2TT Birmingham United Kingdom See on map Region West Midlands (England) West Midlands Birmingham Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Total cost No data Beneficiaries (1) Sort alphabetically Sort by EU Contribution Expand all Collapse all THE UNIVERSITY OF BIRMINGHAM United Kingdom EU contribution € 1 894 046,00 Address Edgbaston B15 2TT Birmingham See on map Region West Midlands (England) West Midlands Birmingham Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Total cost No data